BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced two poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 22–26, 2025 in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced two poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 22–26, 2025 in Boston.
Two abstracts: BBO-11818, an oral non-covalent pan-KRAS(ON)/(OFF) inhibitor showing robust anti-tumor activity in KRAS-mutant preclinical models, will be presented in Poster Session A on Oct 23, 12:30–4:00 PM ET by Carlos Stahlhut, PhD. BBO-10203, a first-in-class oral breaker of the RAS:PI3Kα interaction that inhibited tumor growth without inducing hyperglycemia in KRAS mutant models, will be presented in Poster Session C on Oct 25, 12:30–4:00 PM ET by Kerstin Sinkevicius, PhD. Abstracts are available on the AACR website.
Details
News Market Reaction – BBOT
On Oct 14, the first trading day after this news, BBOT closed 4.19% below the previous close.
Data tracked by StockTitan Argus for the Oct 14 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held on October 22-26, 2025, in Boston, Massachusetts. The abstracts released today can be found on the AACR website here.
Details on the abstracts are as follows:
- Title: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
- Session: Poster Session A
- Session Date/Time: Thursday, October 23, from 12:30 p.m. – 4:00 p.m. ET
- Presenter: Carlos Stahlhut, PhD, Associate Director, BBOT
- Title: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia
- Session: Poster Session C
- Session Date/Time: Saturday, October 25, from 12:30 p.m. – 4:00 p.m. ET
- Presenter: Kerstin Sinkevicius, PhD, Vice President, Pharmacology, BBOT
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.